Recent Advances in Non-Small Cell Lung Cancer

Dear Colleagues,

Significant progress has been made in the field of targeted treatment, immunotherapy and cancer biology since our last Special Issue in 2015 on “Non-Small Cell Lung Cancer Therapies”. After decades of disappointment, cancer immunotherapy treatment has finally come of age, especially with the ability of anti-PD-1 and anti-PD-L1 agents to significantly improve treatment outcome as first- and second-line agents over standard chemotherapy treatment in advanced Non-Small Cell Lung Cancer (NSCLC). In addition, durvalumab, an anti-PD-L1 agent, when used as adjuvant treatment after chemo radiotherapy treatment in stage III NSCLC, was also found to improve outcomes. There were also significant developments seen in the field of targeted treatment. Newer generation targeted TKI agents, osimertinib and alectinib were significantly found to be superior compared to the first-generation agents, with a doubling of PFS outcome. They also have substantial clinical activity against brain metastases. In the field of cancer biology, the TRACERx consortium based in the UK published the first results of their 100 recruited patients which have provided new insights how lung cancer evolves with implications for possible new targeted and immunotherapy for the future.

This Special Issue aims to summarize and update researchers and clinicians as to the remarkable progress made in the field of targeted therapy, immunotherapy and cancer biology made recently for lung cancer.

Prof. Dr. Siow Ming Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• NSCLC
• immunotherapy
• EGFR TKIs
• ALK inhibitors
• tumor heterogeneity
• circulating tumor DNA